Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06131437 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 809
- Enrollment target
NCT06131437: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT06131437 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 809 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06131437, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 809 participants
- Enrollment target
Study Summary
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.
Primary Outcome
Measured in percentage (%).
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
- DRUG Cagrilintide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 809 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2026-01-09 |
| Phase | Phase 3 |
What the finished NCT06131437 record still lists
NCT06131437 is an interventional study that assigns participants to a tested intervention. The registered 809 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Tirzepatide is the first listed.
NCT06131437 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06131437 about?
NCT06131437 is a clinical study titled "A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight". This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections...
What is the current status of trial NCT06131437?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 809 participants. The study started on 2023-11-27. Estimated completion is 2026-01-09.
What interventions are being tested in trial NCT06131437?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Cagrilintide (DRUG).
Who is sponsoring clinical trial NCT06131437?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06131437's enrollment target sits among peer trials
809 410th of 2000 higher than 1,591 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI